The condition is genetic, and the genetic basis depends on the subtype. Inheritance patterns differ by subtype: some forms are autosomal dominant, meaning a child of an affected parent has a fifty percent chance of inheriting the variant, while a rarer form is autosomal recessive, meaning two non-symptomatic carrier parents can have an affected child. The disease-causing variants disrupt the function of small arteries deep in the brain, producing a characteristic vasculopathy of the vessel wall. Recurrence risk should be tied to the confirmed subtype, and genetic counseling clarifies which subtype an individual or family carries.

Diagnosis usually begins when a clinician notices a pattern of unexplained early stroke, migraine with aura, or progressive cognitive change, particularly when more than one family member is affected. Symptoms can overlap with other small vessel diseases, sporadic stroke, multiple sclerosis, and primary psychiatric illness, so molecular genetic testing confirms the diagnosis. Brain MRI is a critical first step and often shows the characteristic distribution of white matter changes along with small deep infarcts and microbleeds. Targeted gene testing or a broader cerebrovascular gene panel identifies the underlying variant and assigns a specific subtype. In selected cases, skin biopsy with electron microscopy can support the diagnosis. A detailed family history helps frame inheritance and identify relatives who may benefit from evaluation.

There are currently no FDA-approved treatments specifically approved for this condition, and no therapy has been shown to modify its long-term course. Care is organized around foundational measures: control of vascular risk factors such as high blood pressure, diabetes, and high cholesterol, smoking cessation, and individualized decisions about antiplatelet therapy. Anticoagulation is generally avoided unless there is a clear separate indication, because affected vessels are prone to microbleeds. Decisions about acute stroke treatments are made cautiously by a stroke specialist. Migraine is treated with standard strategies. Mood and cognitive symptoms benefit from psychiatric support, cognitive rehabilitation, and carefully chosen medications. Regular surveillance is an essential part of long-term care: periodic neurological assessment, interval MRI in selected patients, and screening for depression and cognitive change help guide adjustments to the care plan.

The course is progressive but highly variable. Many individuals live for decades after their first stroke-like event, and the rate at which disability accumulates differs across families and even between siblings. Cognitive impairment and dependency tend to increase over time, and significant disability is common by mid- to late life, although this is not universal. Early diagnosis, sustained vascular risk factor control, and engagement with a multidisciplinary team are associated with better day-to-day functioning. Quality-of-life focused care and caregiver support are integral to long-term management.

Research interest in this group of conditions is active and growing. Several clinical studies are currently underway, including natural history studies, biorepository and genomics efforts, and disease-network registries. Two compounds carry orphan drug designation in this indication, which reflects regulatory recognition of unmet need rather than approval or proven benefit. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team to discuss whether participation is appropriate for their situation.